NCT00780000View on ClinicalTrials.gov

Clinical Trial of Intravenous Alvespimycin in Patients With Her2 Positive Breast Cancer

PHASE2TerminatedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

April 30, 2008

Primary Completion Date

June 30, 2008

Study Completion Date

June 30, 2008

Conditions
Breast Cancer
Interventions
DRUG

Alvespimycin

Solution, IV, Alvespimycin 80 mg/m2, Weekly one hour infusion Days 1, 8, and 15, every 4 weeks thereafter until disease progression or DLT

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY